<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959436</url>
  </required_header>
  <id_info>
    <org_study_id>2017-836</org_study_id>
    <nct_id>NCT03959436</nct_id>
  </id_info>
  <brief_title>Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery</brief_title>
  <official_title>Prospective Observational Database Evaluating Outcomes of Using Carbetocin (Duratocin®) as the Primary Uterotonic Following Cesarean Delivery at Maisonneuve-Rosemont Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carbetocin (Duratocin®) is a long-acting form of oxytocin, with a half-life almost 10 times
      longer. Studies have demonstrated that carbetocin diminishes the need for secondary
      uterotonic agents compared to oxytocin for cesarean delivery (CD). Despite certain Canadian
      guidelines recommending its use for elective CD, several Canadian centers and other countries
      have not adopted carbetocin. The purpose of this study is to prospectively gather electronic
      data on all CDs over a one year period, elective and emergent, in a single institution, and
      to evaluate the efficacy and other clinical outcomes when carbetocin is used as a first line
      uterotonic for all CDs. A database using Microsoft Dynamics CRM is available on smart phones
      and tablets. Data regarding additional uterotonic use and impact of carbetocin use during CD
      on intra and postoperative outcomes are gathered and analyzed. The primary outcome is the use
      of additional uterotonics in this population compared to that described in the literature for
      oxytocin as the primary uterotonic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Actual">March 16, 2018</completion_date>
  <primary_completion_date type="Actual">March 16, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>Use of additional uterotonics</measure>
    <time_frame>24 hours</time_frame>
    <description>The number of participants requiring additional uterotonics after using carbetocin as the initial uterotonic</description>
  </primary_outcome>
  <enrollment type="Actual">612</enrollment>
  <condition>Carbetocin</condition>
  <condition>Cesarean Section Complications</condition>
  <condition>Uterotonics</condition>
  <condition>Uterine Atony With Hemorrhage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Carbetocin as the primary uterotonic for all cesarean sections</description>
    <other_name>Duratocin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients requiring cesarean section.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Cesarean deliveries in the operating room.

        Exclusion Criteria:

          -  Vaginal deliveries and double set-up vaginal deliveries conducted in the operating
             room.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Zaphiratos, MSc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Richebé, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Boucher M, Horbay GL, Griffin P, Deschamps Y, Desjardins C, Schulz M, Wassenaar W. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol. 1998 May-Jun;18(3):202-7.</citation>
    <PMID>9659650</PMID>
  </reference>
  <reference>
    <citation>Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER, Farine D, Schulz ML, Horbay GL, Griffin P, Wassenaar W. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):670-6.</citation>
    <PMID>10076146</PMID>
  </reference>
  <reference>
    <citation>Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009 Nov;280(5):707-12. doi: 10.1007/s00404-009-0973-8. Epub 2009 Feb 20.</citation>
    <PMID>19229549</PMID>
  </reference>
  <reference>
    <citation>Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, Hunt LP, Draycott T. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG. 2010 Jul;117(8):929-36. doi: 10.1111/j.1471-0528.2010.02585.x. Epub 2010 May 19.</citation>
    <PMID>20482535</PMID>
  </reference>
  <reference>
    <citation>Leduc D, Senikas V, Lalonde AB; CLINICAL PRACTICE OBSTETRICS COMMITTEE. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2009 Oct;31(10):980-993. doi: 10.1016/S1701-2163(16)34329-8. Review.</citation>
    <PMID>19941729</PMID>
  </reference>
  <reference>
    <citation>Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD005457. doi: 10.1002/14651858.CD005457.pub4. Review.</citation>
    <PMID>22513931</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Valerie Zaphiratos</investigator_full_name>
    <investigator_title>Unit Chief of Obstetric Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Inertia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To publish this data in a journal. Data includes primary outcomes and secondary outcomes related to uterotonic use and uterine atony and hemorrhage.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Our plan is to publish in the coming year.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

